Afatinib—new therapy option for EGFR-mutant lung cancer
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Afatinib was FDA-approved in 2013 as first-line treatment for metastatic NSCLC with activating EGFR mutations.
“Afatinib (Boehringer Ingelheim) (Figs. 1 and 2b) was approved by the FDA in 2013 as a first-line treatment for patients with metastatic NSCLC with activating mutations in EGFR37,38.”
From Advances in covalent drug discovery (2022) · cites this paper as [38]
The citation lists haven’t been fetched yet
References 10 · Cited by 105
- Authors
- Yu, H. A., & Pao, W.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Vanderbilt University (US)
- Corresponding author
- Pao, William
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2013-08-20
- Volume
- 10
- Issue
- 10
- Pages
- 551-552
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W2060228539
- Cited by
- 105
- References
- 10
- Citations by year
- 2026: 6 · 2025: 14 · 2024: 16 · 2023: 17 · 2022: 7 · 2021: 4 · 2020: 8 · 2019: 7 · 2018: 5 · 2017: 5 · 2016: 6 · 2015: 5 · 2014: 5
- FWCI
- 4.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (R01CA121210)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- afatinib, EGFR-mutant lung cancer, non-small cell lung cancer, exon 19 deletion, L858R mutation, first-line therapy, metastatic lung cancer, FDA approval, tyrosine kinase inhibitors
- MeSH terms
- Afatinib, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Quinazolines, Molecular Targeted Therapy, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
